US clears Alere flu test
Alere Influenza AandB Test
FDA okays Alere Influenza AandB Test for US market
The US Food and Drug Administration (FDA) has cleared the Alere Influenza AandB Test for the US market, categorising it as CLIA-waived.
The test is intended for use in the physician's office and will help healthcare practitioners manage patients with influenza-like illness more effectively.
The US Congress passed the Clinical Laboratory Improvement Amendments (CLIA) in 1988 to set quality standards for all laboratory testing and ensure that tests, no matter where they are performed, deliver accurate, reliable and timely patient results.
In 2008, the FDA, which determines what tests are eligible for waiver, established more stringent guidelines for in-vitro diagnostics to make certain that only accurate and easy-to-use tests reach the physician's office.
In order for a device to be considered for waiver, manufacturers must demonstrate that it is accurate and simple to use in a CLIA-waived environment.
Testing, moreover, must be performed by the intended user - for instance, a nurse, medical assistant, or doctor - as opposed to a specially trained laboratory technologist.
After multiple studies to validate the test and considerable collaboration with the FDA, the Alere Influenza Test has been granted waived status.
Avi Pelossof, vice president, infectious disease at Alere, said: "By getting this product into the waived segment of the marketplace, we are giving healthcare providers a new tool that will enable them to make better decisions about flu diagnosis and treatment while patients are still in the office." The Alere Influenza AandB Test uses highly sensitive antibodies to detect influenza types A and B antigen.
When compared to viral culture, the new Alere test showed performance with sensitivity / specificity of 93.8% / 95.8% for flu A and 77.4% / 98% for flu B.
Sample collection for the Alere Influenza AandB Test, which makes use of a nasal swab, is minimally invasive.
The test also provides results in 10 minutes, making it possible for physicians to administer treatment while patients are still in their care.
The Alere Influenza AandB Test adds a dipstick format test to Alere's existing portfolio of influenza diagnostics, which includes the card format BinaxNOW Influenza AandB Test, enabling Alere to provide primary care physicians with a full range of easy-to-use, effective tools for identifying influenza A and B at the point of care.
The Alere Triage Cardioprofiler assesses patients with chest pain to quickly determine whether they are suffering acute coronary syndrome (ACS), without the need for a lengthy medical assessment.
Alere has re-launched its Determine portfolio of products for the accurate and rapid diagnosis of infectious diseases, including the HIV 1/2 Ag/Ab Combo test, to fit within its new brand image.
Alere has introduced a new diagnostic tool as an aid to the diagnosis of early onset pre-eclampsia - the Alere Triage PLGF test.
According to a study, a point-of-care blood biomarker test for Neutrophil Gelatinase-Associated Lipocalin (NGAL) can help identify patients at risk of severe acute kidney injury (AKI) within a week.
Alere has launched what it claims is the world's first fingerstick b-type natriuretic peptide (BNP) test as an aid for the diagnosis and assessment of severity in patients with heart failure.